Optimizing Starting Materials to Enable Future Scalable Cell Therapy Production

• Providing strategies to effectively isolate key starting materials to enhance product yield
• Assessing cell phenotype and fitness to understand how starting material quality impacts manufacturing success
• Applying engineering and process innovations to improve low quality autologous starting material and enable reliable production for clinical supply

Speakers:

Rudolph Hulspas

Dana-Farber Cancer Institute